<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<title>Interim Analysis and Alpha Spending Functions</title>
<meta name="author" content="By Statistical Innovation"/>
<style type="text/css">
.underline { text-decoration: underline; }
</style>
<link rel="stylesheet" href="./reveal.js/dist/reveal.css"/>

<link rel="stylesheet" href="./reveal.js/dist/theme/serif.css" id="theme"/>

<link rel="stylesheet" href="./presentation.css"/>
<link rel="stylesheet" href="./reveal.js/plugin/highlight/zenburn.css"/>
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
</head>
<body>
<div class="reveal">
<div class="slides">
<section id="sec-title-slide">
<h1 class="title">Interim Analysis and Alpha Spending Functions</h1><h2 class="author">By Statistical Innovation</h2><p class="date">Created: 2024-03-11 Mon 09:42</p>
</section>
<section>
<section id="slide-org64c8219">
<h2 id="org64c8219">An Introduction to Interim Analysis</h2>
<div class="outline-text-2" id="text-org64c8219">
</div>
</section>
</section>
<section>
<section id="slide-orgd90df25">
<h3 id="orgd90df25">An example of RCT</h3>
<ul>
<li>Consider a randomized controlled trial with a continuous endpoint</li>
<li>The <i>goal</i> is to show that the treatment is superior than the control</li>

</ul>

</section>
<section>

<div id="orga6f3f12" class="figure">
<p><img src="./Figures/trialdesign/gsd_rct0.png" alt="gsd_rct0.png" height="400px" />
</p>
</div>

</section>
<section>

<div id="org6aec036" class="figure">
<p><img src="./Figures/trialdesign/gsd_rct1.png" alt="gsd_rct1.png" height="400px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-org05c94ba">
<h3 id="org05c94ba">Interim analysis</h3>
<ul>
<li>An interim analysis is the evaluation of data from a clinical trial before the trial is completed</li>
<li>The purposes of an interim analysis include
<ul>
<li>to ensure the safety of the trial participants</li>
<li>to check the assumptions made at the design stage</li>
<li>to determine if the trial should be stopped due to clear <i>beneficial</i> or
harmful effects of the treatment</li>
<li>to assess if the trial is likely to reach its objectives</li>

</ul></li>

</ul>

</section>
<section>
<ul>
<li>Benefits
<ul>
<li>Participants are not exposed to ineffective or unsafe treatments (ethical)</li>
<li>Sample size, time and cost are not wasted (economic)</li>

</ul></li>

</ul>

</section>
<section>
<ul>
<li>Questions
<ul>
<li>When will the interim analyses occur?</li>
<li>What data will be used?</li>
<li>What statistical methods will be applied?</li>
<li>What are the stopping criteria?</li>

</ul></li>

</ul>
</section>
</section>
<section>
<section id="slide-orgfdf289f">
<h3 id="orgfdf289f">Two concepts related to IA</h3>
<div class="outline-text-3" id="text-orgfdf289f">
</div>
<ul class="org-ul">
<li><a id="org7d6134b"></a>Information fraction<br />
<ul>
<li>Defined as the fraction of <i>total information</i> expected at the scheduled end of
the trial</li>
<li>Roughly, \[\mbox{Information Fraction} = {n \mbox{ at the interim analysis}
  \over N \mbox{ at the final analysis}}\]</li>
<li>For survival analysis, \(n\) and \(N\) are the number of events instead of
subjects</li>

</ul>
</li>
<li><a id="orgf383742"></a>Maturity<br />
<ul>
<li>No uniformly accepted definition of what <i>maturity</i> means</li>
<li>Example
<ul>
<li>Maturity is defined as the proportion of patients that had experienced an
event</li>

</ul></li>
<li>Maturity matters more for the estimation of the <i>survival function</i></li>

</ul>
</li>
</ul>
</section>
</section>
<section>
<section id="slide-orgabc6005">
<h3 id="orgabc6005">The RCT example</h3>

<div id="orgbf951ee" class="figure">
<p><img src="./Figures/trialdesign/gsd_rct3.png" alt="gsd_rct3.png" height="400px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-org7f64617">
<h2 id="org7f64617">Alpha Spending Function</h2>
<div class="outline-text-2" id="text-org7f64617">
</div>
</section>
</section>
<section>
<section id="slide-org45cde52">
<h3 id="org45cde52">Definition</h3>
<ul>
<li>Any function can be an alpha spending function if the function satisfies
<ul>
<li>\(\alpha(0)=0\) (value equals \(0\) at the beginning of the study)</li>
<li>\(\alpha(1)=\alpha\) (value equals \(\alpha\) at the final analysis)</li>
<li>Non-decreasing</li>

</ul></li>
<li>A more flexible group sequential procedure that <i>does not require the total
number nor the exact time of the interim analyses to be specified in advance</i></li>

</ul>
</section>
</section>
<section>
<section id="slide-org6f46f78">
<h3 id="org6f46f78">Alpha spending function examples</h3>
<ul>
<li>Pocock-type spending function
\[\alpha(t) = \alpha \log \{1 + (e-1)t\} \]</li>
<li>OF-type spending function
\[\alpha(t) = 2 \{1 - \Phi(z_{\alpha/2}/\sqrt{t})\}\]</li>

</ul>

</section>
<section>

<div id="org2686dde" class="figure">
<p><img src="./Figures/trialdesign/gsd_af.png" alt="gsd_af.png" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-orgdb61826">
<h3 id="orgdb61826">An illustration</h3>
<ul>
<li>Consider \(\alpha(t) = \alpha t\) with \(\alpha = 0.025\)</li>
<li>Suppose the first IA occurs at \(t = 0.2\)
<ul>
<li>The \(\alpha\) to be spent is \(0.2 \times 0.025 = 0.005\)</li>
<li>The corresponding critical value \(c_1 = 2.576\), such that \(P(Z_1 > c_1) = 0.005\)</li>
<li>Nominal \(\alpha\) at the first IA is \(1 - \Phi(2.576) = 0.005\)</li>

</ul></li>
<li>Suppose rejection does not happen, and the next IA occurs at \(t=0.5\)
<ul>
<li>The \(\alpha\) that can be spent is \(0.5 \times 0.025 = 0.0125\)</li>
<li>The corresponding critical value \(c_2 = 2.377\), such that \(P(Z_1 > 2.576 \cup Z_2
    > c_2) = 0.0125\)</li>
<li>Nominal \(\alpha\) at the second IA is \(1 - \Phi(2.377) = 0.009\)</li>

</ul></li>
<li>Suppose reject still does not happen, at the final analysis \(t=1\)
<ul>
<li>The \(\alpha\) that can be spent is \(0.5 \times 0.025 = 0.025\)</li>
<li>The corresponding critical value \(c_3 = 2.141\), such that \(P(Z_1 > 2.576 \cup Z_2
    > 2.377 \cup Z_3 > c_3) = 0.025\)</li>
<li>Nominal \(\alpha\) at the FA is \(1 - \Phi(2.141) = 0.016\)</li>

</ul></li>

</ul>
</section>
</section>
<section>
<section id="slide-orgd45108a">
<h2 id="orgd45108a">A Case Study</h2>
<div class="outline-text-2" id="text-orgd45108a">
</div>
</section>
</section>
<section>
<section id="slide-orga633eec">
<h3 id="orga633eec">Primary and secondary endpoint</h3>
<ul>
<li>Primary
<ul>
<li>Disease free survival (DFS)</li>

</ul></li>
<li>Secondary
<ul>
<li>DFS rate at 2, 3 and 5 years</li>
<li>Overall Survival (OS)</li>
<li>OS rate at 5 years</li>

</ul></li>

</ul>
</section>
</section>
<section>
<section id="slide-org3637460">
<h3 id="org3637460">Interim analysis plan (i)</h3>
<ul>
<li>The primary analysis was planned to be conducted when approximately 247 DFS
events were observed in the stage II/IIIA population</li>
<li>After a planned meeting in 2019 to assess futility, but not superiority, when
at least 83 disease recurrence events or deaths had occurred in patients with
stage II to IIIA disease, the committee requested assessment of efficacy data
at the next scheduled meeting for safety (April 2020)</li>
<li>On the basis of review of these data, the committee recommended that the
trial be unblinded at a trial level early to complete primary reporting</li>

</ul>
</section>
</section>
<section>
<section id="slide-org8ff512e">
<h3 id="org8ff512e">Interim analysis plan (ii)</h3>
<ul>
<li>Two <b>unplanned interim analysis</b> of DFS in the stage II/IIIA population were
conducted at the time of observing 86 DFS events and 156 DFS events
respectively</li>
<li>The corresponding information fractions were 0.35 and 0.63 where the final
number of events would have been 247</li>
<li>The Lan DeMets approach that approximates the Oâ€™Brien and Fleming spending
function will be used to maintain an overall 2-sided 5% type I error</li>

</ul>
</section>
</section>
<section>
<section id="slide-org74fcb5c">
<h3 id="org74fcb5c">Interim analysis plan (iii)</h3>

<div id="orge1e87d4" class="figure">
<p><img src="Figures/trialdesign/case3_tb.png" alt="case3_tb.png" height="400px" />
</p>
</div>
</section>
</section>
<section>
<section id="slide-orgd9b8bbb">
<h2 id="orgd9b8bbb">Potential Limitations</h2>
<div class="outline-text-2" id="text-orgd9b8bbb">
</div>
</section>
</section>
<section>
<section id="slide-org2155e10">
<h3 id="org2155e10">Overestimation of the effect size</h3>
<ul>
<li>A trial terminated early for benefit will tend to overestimate the treatment
effect</li>
<li>Extreme p-values are more likely obtained when there is a random &ldquo;high&rdquo;
treatment effect</li>
<li>Statistical methods exist for adjusting the overestimation bias
<ul>
<li>Not commonly applied in practice</li>

</ul></li>
<li>It is important to understand the overestimation issue in decision making</li>
<li><i>Zhang, Jenny J., et al. Overestimation of the Effect Size in Group Sequential
Trials. Clinical Cancer Research 18.18 (2012)</i></li>

</ul>
</section>
</section>
<section>
<section id="slide-org1505499">
<h3 id="org1505499">Clinical relevance (i)</h3>
<ul>
<li><i>Oncologic Drugs Advisory Committee (ODAC) Meeting, February 9, 2021. BLA
125514 Supplement-089</i></li>
<li>KEYNOTE-522
<ul>
<li>Pembrolizumab vs placebo in combination with chemotherapy in the neoadjuvant
setting and as monotherapy in the adjuvant setting in 1174 patients with
high-risk, early-stage TNBC</li>
<li>The co-primary endpoints are pathologic complete response (pCR) rate and
event-free survival (EFS)</li>

</ul></li>
<li>pCR at IA1
<ul>
<li>Pembrolizumab: \(64.8 (59.9, 69.5)\), \(n = 401\)</li>
<li>Placebo: \(51.2 (44.1, 58.3)\), \(n=201\)</li>
<li>p-value \(0.00055\)</li>

</ul></li>

</ul>
</section>
</section>
<section>
<section id="slide-org202a775">
<h3 id="org202a775">Clinical relevance (ii)</h3>
<ul>
<li>The FDA&rsquo;s position
<ul>
<li>FDA does not agree that the small pCR rate difference between treatment arms
is clinically meaningful</li>
<li>Interim analyses may overestimate the treatment effect, particularly when
the number of events is small</li>
<li>The data are not sufficiently mature for FDA to consider these interim EFS
results as a reliable estimate of the EFS treatment effect</li>
<li>While FDA agrees that pCR was statistically significant at IA1, FDA
considers pCR at IA3 to be the most accurate estimate of the pCR difference
between treatment arms since this estimate includes all patients who were
randomized</li>

</ul></li>

</ul>
</section>
</section>
</div>
</div>
<script src="./reveal.js/dist/reveal.js"></script>
<script src="./reveal.js/plugin/markdown/markdown.js"></script>
<script src="./reveal.js/plugin/highlight/highlight.js"></script>
<script>
// Full list of configuration options available here:
// https://github.com/hakimel/reveal.js#configuration
Reveal.initialize({

controls: true,
progress: true,
history: false,
center: true,
slideNumber: false,
rollingLinks: false,
keyboard: true,
mouseWheel: false,
fragmentInURL: false,
hashOneBasedIndex: false,
pdfSeparateFragments: true,
overview: true,
margin: 0.10,

transition: 'convex',
transitionSpeed: 'default',

// Plugins with reveal.js 4.x
plugins: [ RevealMarkdown, RevealHighlight ],

// Optional libraries used to extend reveal.js
dependencies: [
]

});
</script>
</body>
</html>
